Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Impairment in Neuro-Behcet's and Behcet's Disease
Autoimmune Neurology
P16 - Poster Session 16 (5:30 PM-6:30 PM)
15-001

We aimed to evaluate the cognitive impairment in Neuro-Behcet's and Behcet's Disease and compare the affected mechanism causing cognitive dysfunction.

Behcet’s disease (BD) is a recurrent multisystemic inflammatory disorder characterized by oral aphtae, genital ulcers, other skin lesions, and uveitis. In about 5%–15% of the cases, it may affect the central nervous system (CNS) parenchyma causing a meningoencephalitis most commonly affecting the brainstem and diencephalic structures and called Neuro-Behcet’s disease (NBD). The impact of BD on higher cognitive functions is still poorly understood and few reports showed that attention, working memory, retrieval abilities, and executive functions affected in NBS. 

36 BD patients and 41 NBS patients were included. All patients were meeting the criteria of International Study Group for BD. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) consisting of the selective reminding, 10/36 spatial recall, symbol digit modalities, paced auditory serial addition (PASAT) and word list generation tests and Beck Depression Scales which is implemented for the measurement of cognitive impairment in BD and MBS patients

44 male and 33 female patient and all of the patients were literated. %75 of the NBS and %38 of the BD patients had cognitive dysfunction. Male gender is a risk factor for cognitive impairment both in NBD and BD. Attention and short-term retention capacities are frequently affected cognitive domains in BD. Visual spatial, verbal modalities are moreover affected in NBD  

%75 of NBD and %38 of BD had cognitive dysfunction at least one domain therefore cognitive dysfunction in BD should be considered carefully beside neurological impairment. Cognitive disorders affect moods and reduce their quality of life. Further comparative studies among patients with NBD and BD are required to discover the mechanisms causing cognitive dysfunction 

Authors/Disclosures
Merve Atik, MD (Mayo Clinic)
PRESENTER
Dr. Atik has nothing to disclose.
No disclosure on file
Melih Tutuncu, MD (ISTANBUL UNIVERSITESI CERRAHPASA TIP FAKULTESI) Dr. Tutuncu has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa) Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
No disclosure on file
Sabahattin Saip Sabahattin Saip has nothing to disclose.
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.